Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 37Carboplatin 26Radiotherapy 23Cisplatin 19Paclitaxel 18Erlotinib Hydrochloride 18Docetaxel 15Gemcitabine 14Pemetrexed 13Etoposide 12osimertinib 11Nivolumab 11durvalumab 9atezolizumab 9Radiosurgery 8Magnetic Resonance Spectroscopy 8Cetuximab 7Specimen Handling 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6Taxes 5Immunoglobulin G 5Gefitinib 5Biopsy 5Bevacizumab 5fludarabine 4Radiation 4Ipilimumab 4Disulfides 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lung Neoplasms × CIMAvax EGF × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡